Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability and willingness to provide written informed consent.~* All individuals who will undergo TRUSP as part of their standard of care are eligible for study.~Exclusion Criteria:~* Men under 30 years of age~* Individuals whose rectal swab indicates that they harbor CS-GNB who cannot receive ciprofloxacin as pre-procedure prophylaxis for any reason~* Individuals whose rectal swab indicates that they harbor CR-GNB who cannot abide by the antimicrobial prophylaxis guidelines outlined in the study protocol for any reason~* Individuals who do not wish to complete the pre-procedure risk factor questionnaire or the two post-procedure phone questionnaires to assess for infectious complications

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Cipro-susceptible (Type: OTHER): Patients with ciprofloxacin-susceptible bacteria on their rectal swab cultures will receive ciprofloxacin, the standard of care, as prophylaxis for their prostate biopsy
- Cipro-resistant (Type: ACTIVE_COMPARATOR): Patients with ciprofloxacin-resistant bacteria on their rectal swab will receive one of the following drugs:~* trimethoprim-sulfamethoxazole 1 double strength tablet orally 2 hours before the procedure and again 12 hours later~* cefuroxime 500 mg orally 2 hours before the procedure then again 12 hours later~* ceftriaxone 500 mg intramuscularly 2 hours before the procedure~* gentamicin 2mg/kg intramuscularly 2 hours before the procedure~* amikacin 5 mg/kg intramuscularly 2 hours before the procedure~* aztreonam 500 mg intramuscularly 2 hours before the procedure~* imipenem 500 mg intramuscularly 2 hours before the procedure~* ceftriaxone 2000 mg intravenously 1 hour before the procedure~* gentamicin 2 mg/kg intravenously 1 hour before the procedure~* amikacin 5mg/kg intravenously 1 hour before the procedure~* aztreonam 2000 mg intravenously 1 hour before the procedure~* imipenem 1000 mg intravenously 1 hour before the procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).